NFκB in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12

Gastroenterology

Volumn 155, Issue 3, 2018, Pages 880-891.e8

  Garg, Bharti ^a   Giri, Bhuwan ^a   Modi, Shrey ^a   Sethi, Vrishketan ^a   Castro, Iris ^a   Umland, Oliver ^a   Ban, Yuguang ^a   Lavania, Shweta ^a   Dawra, Rajinder ^a   Banerjee, Sulagna ^a   Vickers, Selwyn ^b   Merchant, Nipun B ^a   Chen, Steven Xi ^a   Gilboa, Eli ^a   Ramakrishnan, Sundaram ^a   Saluja, Ashok ^a   Dudeja, Vikas ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Kentucky   (United States)

Author keywords

Chemokine; CXCR4; Cytokine; Immune Suppression

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; CXCL12 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B16-F10 CELL LINE; CANCER CELL; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL DEATH; CELL INFILTRATION; CELL KILLING; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FIBROBLAST; GENE DELETION; IN VITRO STUDY; LEWIS LUNG CARCINOMA CELL LINE; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC STELLATE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CELLULAR IMMUNITY; IMMUNOLOGY; METABOLISM; PANCREAS TUMOR; PHYSIOLOGY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CHEMOKINE CXCL12; IMMUNITY, CELLULAR; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; NF-KAPPA B; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 85051678735     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2018.05.051     Document Type: Article

References (30)

1. Burnet, F.M., The concept of immunological surveillance. Prog Exp Tumor Res 13 (1970), 1–27.
2. Kaplan, H.S., Role of immunologic disturbance in human oncogenesis: some facts and fancies. Br J Cancer 25 (1971), 620–634.
3. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
4. Vinay, D.S., Ryan, E.P., Pawelec, G., et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 35:Suppl (2015), S185–S198.
5. Swann, J.B., Smyth, M.J., Immune surveillance of tumors. J Clin Invest 117 (2007), 1137–1146.
6. Kim, R., Emi, M., Tanabe, K., Cancer immunoediting from immune surveillance to immune escape. Immunology 121 (2007), 1–14.
7. Drake, C.G., Jaffee, E., Pardoll, D.M., Mechanisms of immune evasion by tumors. Adv Immunol 90 (2006), 51–81.
8. Weber, J.S., Current perspectives on immunotherapy. Semin Oncol 41:Suppl 5 (2014), S14–S29.
9. Alexandrescu, D.T., Ichim, T.E., Riordan, N.H., et al. Immunotherapy for melanoma: current status and perspectives. J Immunother 33 (2010), 570–590.
10. Wormann, S.M., Diakopoulos, K.N., Lesina, M., et al. The immune network in pancreatic cancer development and progression. Oncogene 33 (2014), 2956–2967.
11. Pure, E., Lo, A., Can Targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors?. Cancer Immunol Res 4 (2016), 269–278.
12. Delitto, D., Delitto, A.E., DiVita, B.B., et al. Human pancreatic cancer cells induce a MyD88-dependent stromal response to promote a tumor-tolerant immune microenvironment. Cancer Res 77 (2017), 672–683.
13. Feig, C., Jones, J.O., Kraman, M., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 110 (2013), 20212–20217.
14. Hingorani, S.R., Wang, L., Multani, A.S., et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 (2005), 469–483.
15. Sha, W.C., Liou, H.C., Tuomanen, E.I., et al. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80 (1995), 321–330.
16. Apte, M.V., Haber, P.S., Applegate, T.L., et al. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 43 (1998), 128–133.
17. Corbett, T.H., Roberts, B.J., Leopold, W.R., et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44 (1984), 717–726.
18. Mombaerts, P., Iacomini, J., Johnson, R.S., et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68 (1992), 869–877.
19. Godfrey, D.I., Stankovic, S., Baxter, A.G., Raising the NKT cell family. Nat Immunol 11 (2010), 197–206.
20. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
21. Maitra, A., Hruban, R.H., Pancreatic cancer. Annu Rev Pathol 3 (2008), 157–188.
22. Moffitt, R.A., Marayati, R., Flate, E.L., et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 47 (2015), 1168–1178.
23. Lee, K.E., Bar-Sagi, D., Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 18 (2010), 448–458.
24. Ling, J., Kang, Y., Zhao, R., et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21 (2012), 105–120.
25. Nomura, A., McGinn, O., Dudeja, V., et al. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer. Mol Cancer, 14, 2015, 200.
26. Teicher, B.A., Fricker, S.P., CXCL12 (SDF-1)/CXCR4 Pathway in cancer. Clin Cancer Res 16 (2010), 2927–2931.
27. Colamussi, M.L., Secchiero, P., Gonelli, A., et al. Stromal derived factor-1 alpha (SDF-1 alpha) induces CD4+ T cell apoptosis via the functional up-regulation of the Fas (CD95)/Fas ligand (CD95L) pathway. J Leukoc Biol 69 (2001), 263–270.
28. Righi, E., Kashiwagi, S., Yuan, J., et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 71 (2011), 5522–5534.
29. Vianello, F., Papeta, N., Chen, T., et al. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J Immunol 176 (2006), 2902–2914.
30. Bradford, J.W., Baldwin, A.S., IKK/nuclear factor-kappaB and oncogenesis: roles in tumor-initiating cells and in the tumor microenvironment. Adv Cancer Res 121 (2014), 125–145.